Top

BMC Urology

Published in:

Open Access 01-12-2024 | Biomarkers | Research

Survival and clinicopathological significance of B7-H3 in bladder cancer: a systematic review and meta-analysis

Authors: Haohao sun, Fei Gao, Yuan Liu, Jianfeng Shao

Published in: BMC Urology | Issue 1/2024

Abstract

Background

B7-H3 has been implicated in clinical pathological features and prognosis across various cancer types, suggesting its potential as a cancer biomarker. Nevertheless, consensus remains elusive regarding its clinical-pathological and prognostic significance in bladder cancer. To address this gap, we conducted a systematic review and meta-analysis.

Methods

We systematically searched PubMed, Embase, Web of Science, Cochrane, and CNKI databases from their inception up to October 6, 2022. We evaluated the literature’s quality using the Newcastle-Ottawa Scale. We performed meta-analysis using Review Manager 5.3 and STATA 12.0, synthesizing data and calculating odds ratios (ORs) or hazard ratios (HRs) with corresponding 95% confidence intervals (CIs).

Results

After applying eligibility criteria and conducting assessments, we included data from 8 studies, encompassing 1622 bladder cancer patients. Bladder tumor tissues exhibited significantly elevated B7-H3 protein expression compared to normal bladder tissues. Elevated B7-H3 expression was notably associated with patient age, tumor infiltration, and recurrence in bladder cancer. However, no significant correlations were observed with other clinical characteristics. Our pooled HR analysis indicated no significant association between B7-H3 expression and overall survival in bladder cancer patients.

Conclusion

Our meta-analysis unveils the complex role of B7-H3 in bladder cancer progression. It appears to be directly involved in tumor infiltration and recurrence but cannot definitively serve as a prognostic biomarker for bladder cancer. To validate these findings, further well-designed studies, encompassing larger sample sizes and diverse racial backgrounds, are warranted.

PROSPERO registration

No. CRD42022364688.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRef

Kubota Y, Nakaigawa N. Essential content of evidence-based clinical practice guidelines for bladder cancer: the Japanese Urological Association 2015 update. Int J Urology: Official J Japanese Urol Association. 2016;23(8):640–5. https://doi.org/10.1111/iju.13141.CrossRef

Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, et al. NCCN guidelines insights: bladder Cancer, Version 2.2016. J Natl Compr Cancer Network: JNCCN. 2016;14(10):1213–24. https://doi.org/10.6004/jnccn.2016.0131.CrossRefPubMed

Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, et al. EAU guidelines on Non-muscle-invasive Urothelial Carcinoma of the bladder: Update 2016. Eur Urol. 2017;71(3):447–61. https://doi.org/10.1016/j.eururo.2016.05.041.CrossRefPubMed

Wang G, Black PC, Goebell PJ, Ji L, Cordon-Cardo C, Schmitz-Dräger B, Hawes D, Czerniak B, Minner S, Sauter G, et al. Prognostic markers in pT3 bladder cancer: a study from the international bladder cancer tissue microarray project. Urol Oncol. 2021;39(5):301. https://doi.org/10.1016/j.urolonc.2021.01.021.CrossRefPubMedCentral

Fouad H, Salem H, Ellakwa DE, Abdel-Hamid M. MMP-2 and MMP-9 as prognostic markers for the early detection of urinary bladder cancer. J Biochem Mol Toxicol. 2019;33(4):e22275. https://doi.org/10.1002/jbt.22275.CrossRefPubMed

Awadalla A, Abol-Enein H, Hamam ET, Ahmed AE, Khirallah SM, El-Assmy A, Mostafa SA, Babalghith AO, Ali M, Abdel-Rahim M, et al. Identification of epigenetic interactions between miRNA and gene expression as potential prognostic markers in bladder Cancer. Genes. 2022;13(9). https://doi.org/10.3390/genes13091629.

Breyer J, Wirtz RM, Otto W, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, et al. Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from Formalin fixed TUR biopsies. Oncotarget. 2017;8(40):67684–95. https://doi.org/10.18632/oncotarget.18804.CrossRefPubMedPubMedCentral

Azevedo R, Soares J, Peixoto A, Cotton S, Lima L, Santos LL, Ferreira JA. Circulating tumor cells in bladder cancer: emerging technologies and clinical implications foreseeing precision oncology. Urol Oncol. 2018;36(5):221–36. https://doi.org/10.1016/j.urolonc.2018.02.004.CrossRefPubMed

10.

Murlidhar V, Reddy RM, Fouladdel S, Zhao L, Ishikawa MK, Grabauskiene S, Zhang Z, Lin J, Chang AC, Carrott P, et al. Poor prognosis indicated by venous circulating tumor cell clusters in early-stage lung cancers. Cancer Res. 2017;77(18):5194–206. https://doi.org/10.1158/0008-5472.Can-16-2072.CrossRefPubMedPubMedCentral

11.

Yu JJ, Xiao W, Dong SL, Liang HF, Zhang ZW, Zhang BX, Huang ZY, Chen YF, Zhang WG, Luo HP, et al. Effect of surgical liver resection on circulating tumor cells in patients with hepatocellular carcinoma. BMC Cancer. 2018;18(1):835. https://doi.org/10.1186/s12885-018-4744-4.CrossRefPubMedPubMedCentral

12.

Jansson S, Bendahl PO, Larsson AM, Aaltonen KE, Rydén L. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort. BMC Cancer. 2016;16:433. https://doi.org/10.1186/s12885-016-2406-y.CrossRefPubMedPubMedCentral

13.

Crocetto F, Cimmino A, Ferro M, Terracciano D. Circulating tumor cells in bladder cancer: a new horizon of liquid biopsy for precision medicine. J Basic Clin Physiol Pharmacol. 2022;33(5):525–7. https://doi.org/10.1515/jbcpp-2021-0233.CrossRefPubMed

14.

van Oers JM, Zwarthoff EC, Rehman I, Azzouzi AR, Cussenot O, Meuth M, Hamdy FC, Catto JW. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol. 2009;55(3):650–7. https://doi.org/10.1016/j.eururo.2008.06.013.CrossRefPubMed

15.

van Rhijn BW, van der Kwast TH, Liu L, Fleshner NE, Bostrom PJ, Vis AN, Alkhateeb SS, Bangma CH, Jewett MA, Zwarthoff EC, et al. The FGFR3 mutation is related to favorable pT1 bladder cancer. J Urol. 2012;187(1):310–4. https://doi.org/10.1016/j.juro.2011.09.008.CrossRefPubMed

16.

Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, Calvo E, Moreno V, Adamo B, Gazzah A, et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with Advanced Solid tumors. J Clin Oncology: Official J Am Soc Clin Oncol. 2015;33(30):3401–8. https://doi.org/10.1200/jco.2014.60.7341.CrossRef

17.

Schuler M, Cho BC, Sayehli CM, Navarro A, Soo RA, Richly H, Cassier PA, Tai D, Penel N, Nogova L, et al. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol. 2019;20(10):1454–66. https://doi.org/10.1016/s1470-2045(19)30412-7.CrossRefPubMed

18.

Necchi A, Castellano DE, Mellado B, Pang S, Urun Y, Park SH, Vaishampayan UN, Currie G, Abella-Dominicis E, Pal SK. Fierce-21: phase II study of vofatmab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC). J Clin Oncol. 2019;37(7). https://doi.org/10.1200/JCO.2019.37.7_suppl.409.

19.

Kriegmair MC, Wirtz RM, Worst TS, Breyer J, Ritter M, Keck B, Boehmer C, Otto W, Eckstein M, Weis CA, et al. Prognostic value of molecular breast Cancer subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in muscle invasive bladder Cancer. Translational Oncol. 2018;11(2):467–76. https://doi.org/10.1016/j.tranon.2018.02.001.CrossRef

20.

Nedjadi T, Al-Maghrabi J, Assidi M, Dallol A, Al-Kattabi H, Chaudhary A, Al-Sayyad A, Al-Ammari A, Abuzenadah A, Buhmeida A, et al. Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques. BMC Cancer. 2016;16:653. https://doi.org/10.1186/s12885-016-2703-5.CrossRefPubMedPubMedCentral

21.

Rodriguez Pena MDC, Chaux A, Eich ML, Tregnago AC, Taheri D, Borhan W, Sharma R, Rezaei MK, Netto GJ. Immunohistochemical assessment of basal and luminal markers in non-muscle invasive urothelial carcinoma of bladder. Virchows Archiv: Int J Pathol. 2019;475(3):349–56. https://doi.org/10.1007/s00428-019-02618-5.CrossRef

22.

Tekle C, Nygren MK, Chen YW, Dybsjord I, Nesland JM, Maelandsmo GM, Fodstad O. B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes. Int J Cancer. 2012;130(10):2282–90. https://doi.org/10.1002/ijc.26238.CrossRefPubMed

23.

Picarda E, Ohaegbulam KC, Zang X. Molecular pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy. Clin cancer Research: Official J Am Association Cancer Res. 2016;22(14):3425–31. https://doi.org/10.1158/1078-0432.Ccr-15-2428.CrossRef

24.

Mao Y, Li W, Chen K, Xie Y, Liu Q, Yao M, Duan W, Zhou X, Liang R, Tao M. B7-H1 and B7-H3 are independent predictors of poor prognosis in patients with non-small cell lung cancer. Oncotarget. 2015;6(5):3452–61. https://doi.org/10.18632/oncotarget.3097.CrossRefPubMed

25.

Ma J, Ma P, Zhao C, Xue X, Han H, Liu C, Tao H, Xiu W, Cai J, Zhang M. B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy. Oncotarget. 2016;7(20):29480–91. https://doi.org/10.18632/oncotarget.8784.CrossRefPubMedPubMedCentral

26.

Kang FB, Wang L, Jia HC, Li D, Li HJ, Zhang YG, Sun DX. B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2/STAT3/Slug signaling pathway. Cancer Cell Int. 2015;15:45. https://doi.org/10.1186/s12935-015-0195-z.CrossRefPubMedPubMedCentral

27.

Benzon B, Zhao SG, Haffner MC, Takhar M, Erho N, Yousefi K, Hurley P, Bishop JL, Tosoian J, Ghabili K, et al. Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis. Prostate Cancer Prostatic Dis. 2017;20(1):28–35. https://doi.org/10.1038/pcan.2016.49.CrossRefPubMed

28.

Wang S, Zhang X, Ning H, Dong S, Wang G, Sun R. B7 homolog 3 induces lung metastasis of breast cancer through Raf/MEK/ERK axis. Breast Cancer Res Treat. 2022;193(2):405–16. https://doi.org/10.1007/s10549-022-06520-8.CrossRefPubMed

29.

Shao X, Zhan S, Quan Q, Shen Y, Chen S, Zhang X, Li R, Liu M, Cao L. Clinical significance of B7-H3 and HER2 co-expression and therapeutic value of combination treatment in gastric cancer. Int Immunopharmacol. 2022;110:108988. https://doi.org/10.1016/j.intimp.2022.108988.CrossRefPubMed

30.

Lee JH, Kim YJ, Ryu HW, Shin SW, Kim EJ, Shin SH, Park JY, Kim SY, Hwang CS, Na JY, et al. B7-H3 expression is associated with high PD-L1 expression in clear cell renal cell carcinoma and predicts poor prognosis. Diagn Pathol. 2023;18(1):36. https://doi.org/10.1186/s13000-023-01320-0.CrossRefPubMedPubMedCentral

31.

Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5. https://doi.org/10.1007/s10654-010-9491-z.CrossRefPubMed

32.

Zhili X, Ling w, Jianhua T, Changchun L, 满宏伟. 李鹏飞, 单亚楠, 单保恩: the association and prognostic significance of B7-H3 with CD68 + tumor-associated macrophages in urothelial cell carcinoma. Chin J Urol. 2016;37(06):470–4. https://doi.org/10.3760/cma.j.issn.1000-6702.2016.06.019. (in Chinese).CrossRef

33.

Xylinas E, Robinson BD, Kluth LA, Volkmer BG, Hautmann R, Küfer R, Zerbib M, Kwon E, Thompson RH, Boorjian SA, et al. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol. 2014;40(1):121–7. https://doi.org/10.1016/j.ejso.2013.08.023.CrossRefPubMed

34.

Xu Z-L, Zhang Y, Wang L, Li F, Man H-W, Li P-F, Shan B-E. B7-H3 promotes malignant progression of muscle-invasive bladder cancer. Oncol Rep. 2018;40(5):2722–33. https://doi.org/10.3892/or.2018.6655.CrossRefPubMed

35.

Xu Z, Wang L, Tian J, Man H, Li P, Shan B. High expression of B7-H3 and CD163 in cancer tissues indicates malignant clinicopathological status and poor prognosis of patients with urothelial cell carcinoma of the bladder. Oncol Lett. 2018;15(5):6519–26. https://doi.org/10.3892/ol.2018.8173.CrossRefPubMedPubMedCentral

36.

Mahmoud AM, Frank I, Orme JJ, Lavoie RR, Thapa P, Costello BA, Cheville JC, Gupta S, Dong H, Lucien F. Evaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer. BMC Urol. 2022;22(1). https://doi.org/10.1186/s12894-022-01044-1.

37.

Li Y, Guo G, Song J, Cai Z, Yang J, Chen Z, Wang Y, Huang Y, Gao Q. B7-H3 promotes the migration and invasion of human bladder cancer cells via the PI3K/Akt/STAT3 signaling pathway. J Cancer. 2017;8(5):816–24. https://doi.org/10.7150/jca.17759.CrossRefPubMedPubMedCentral

38.

Boorjian SA, Sheinin Y, Crispen PL, Farmer SA, Lohse CM, Kuntz SM, Leibovich BC, Kwon ED, Frank I. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res. 2008;14(15):4800–8. https://doi.org/10.1158/1078-0432.Ccr-08-0731.CrossRefPubMed

39.

Azuma T, Sato Y, Ohno T, Azuma M, Kume H. Serum soluble B7-H3 is a prognostic marker for patients with non-muscle-invasive bladder cancer. PLoS ONE. 2020;15(12 December). https://doi.org/10.1371/journal.pone.0243379.

40.

Kontos F, Michelakos T, Kurokawa T, Sadagopan A, Schwab JH, Ferrone CR, Ferrone S. B7-H3: an attractive target for antibody-based Immunotherapy. Clin cancer Research: Official J Am Association Cancer Res. 2021;27(5):1227–35. https://doi.org/10.1158/1078-0432.Ccr-20-2584.CrossRef

41.

Vigdorovich V, Ramagopal UA, Lázár-Molnár E, Sylvestre E, Lee JS, Hofmeyer KA, Zang X, Nathenson SG, Almo SC. Structure and T cell inhibition properties of B7 family member, B7-H3. Structure. 2013;21(5):707–17. https://doi.org/10.1016/j.str.2013.03.003.CrossRefPubMedPubMedCentral

42.

Seaman S, Zhu Z, Saha S, Zhang XM, Yang MY, Hilton MB, Morris K, Szot C, Morris H, Swing DA, et al. Eradication of tumors through simultaneous ablation of CD276/B7-H3-Positive tumor cells and Tumor vasculature. Cancer Cell. 2017;31(4):501–515e508. https://doi.org/10.1016/j.ccell.2017.03.005.CrossRefPubMedPubMedCentral

43.

Cong F, Yu H, Gao X. Expression of CD24 and B7-H3 in breast cancer and the clinical significance. Oncol Lett. 2017;14(6):7185–90. https://doi.org/10.3892/ol.2017.7142.CrossRefPubMedPubMedCentral

44.

Yonesaka K, Haratani K, Takamura S, Sakai H, Kato R, Takegawa N, Takahama T, Tanaka K, Hayashi H, Takeda M, et al. B7-H3 negatively modulates CTL-Mediated Cancer Immunity. Clin cancer Research: Official J Am Association Cancer Res. 2018;24(11):2653–64. https://doi.org/10.1158/1078-0432.Ccr-17-2852.CrossRef

45.

Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, Wilton A, Thaler HT, Arul M, Slovin SF, Wei J, et al. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol. 2010;23(8):1104–12. https://doi.org/10.1038/modpathol.2010.95.CrossRefPubMedPubMedCentral

46.

Nunes-Xavier CE, Karlsen KF, Tekle C, Pedersen C, Øyjord T, Hongisto V, Nesland JM, Tan M, Sahlberg KK, Fodstad Ø. Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors. Oncotarget. 2016;7(6):6891–901. https://doi.org/10.18632/oncotarget.6902.CrossRefPubMedPubMedCentral

47.

Chen L, Chen J, Xu B, Wang Q, Zhou W, Zhang G, Sun J, Shi L, Pei H, Wu C, et al. B7-H3 expression associates with tumor invasion and patient’s poor survival in human esophageal cancer. Am J Translational Res. 2015;7(12):2646–60.

48.

Sun J, Guo YD, Li XN, Zhang YQ, Gu L, Wu PP, Bai GH, Xiao Y. B7-H3 expression in breast cancer and upregulation of VEGF through gene silence. OncoTargets Therapy. 2014;7:1979–86. https://doi.org/10.2147/ott.S63424.CrossRefPubMedPubMedCentral

49.

Zhao X, Li DC, Zhu XG, Gan WJ, Li Z, Xiong F, Zhang ZX, Zhang GB, Zhang XG, Zhao H. B7-H3 overexpression in pancreatic cancer promotes tumor progression. Int J Mol Med. 2013;31(2):283–91. https://doi.org/10.3892/ijmm.2012.1212.CrossRefPubMed

50.

Zhong C, Tao B, Chen Y, Guo Z, Yang X, Peng L, Xia X, Chen L. B7-H3 regulates Glioma Growth and Cell Invasion through a JAK2/STAT3/Slug-Dependent signaling pathway. OncoTargets Therapy. 2020;13:2215–24. https://doi.org/10.2147/ott.S237841.CrossRefPubMedPubMedCentral

51.

Zhao X, Zhang GB, Gan WJ, Xiong F, Li Z, Zhao H, Zhu DM, Zhang B, Zhang XG, Li DC. Silencing of B7-H3 increases gemcitabine sensitivity by promoting apoptosis in pancreatic carcinoma. Oncol Lett. 2013;5(3):805–12. https://doi.org/10.3892/ol.2013.1118.CrossRefPubMedPubMedCentral

52.

Ingebrigtsen VA, Boye K, Tekle C, Nesland JM, Flatmark K, Fodstad O. B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer. Int J Cancer. 2012;131(11):2528–36. https://doi.org/10.1002/ijc.27566.CrossRefPubMed

53.

Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, Thompson RH, Boorjian SA, Dong H, Leibovich BC, et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin cancer Research: Official J Am Association Cancer Res. 2008;14(16):5150–7. https://doi.org/10.1158/1078-0432.Ccr-08-0536.CrossRef

54.

Kang FB, Wang L, Li D, Zhang YG, Sun DX. Hepatocellular carcinomas promote tumor-associated macrophage M2-polarization via increased B7-H3 expression. Oncol Rep. 2015;33(1):274–82. https://doi.org/10.3892/or.2014.3587.CrossRefPubMed

55.

Lu H, Shi T, Wang M, Li X, Gu Y, Zhang X, Zhang G, Chen W. B7-H3 inhibits the IFN-γ-dependent cytotoxicity of Vγ9Vδ2 T cells against colon cancer cells. Oncoimmunology. 2020;9(1):1748991. https://doi.org/10.1080/2162402x.2020.1748991.CrossRefPubMedPubMedCentral

56.

Loo D, Alderson RF, Chen FZ, Huang L, Zhang W, Gorlatov S, Burke S, Ciccarone V, Li H, Yang Y, et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin cancer Research: Official J Am Association Cancer Res. 2012;18(14):3834–45. https://doi.org/10.1158/1078-0432.Ccr-12-0715.CrossRef

57.

Lee YH, Martin-Orozco N, Zheng P, Li J, Zhang P, Tan H, Park HJ, Jeong M, Chang SH, Kim BS, et al. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Res. 2017;27(8):1034–45. https://doi.org/10.1038/cr.2017.90.CrossRefPubMedPubMedCentral

58.

Kasten BB, Arend RC, Katre AA, Kim H, Fan J, Ferrone S, Zinn KR, Buchsbaum DJ. B7-H3-targeted (212)pb radioimmunotherapy of ovarian cancer in preclinical models. Nucl Med Biol. 2017;47:23–30. https://doi.org/10.1016/j.nucmedbio.2017.01.003.CrossRefPubMedPubMedCentral

59.

Ma W, Ma J, Ma P, Lei T, Zhao M, Zhang M. Targeting immunotherapy for bladder cancer using anti-CD3× B7-H3 bispecific antibody. Cancer Med. 2018;7(10):5167–77. https://doi.org/10.1002/cam4.1775.CrossRefPubMedPubMedCentral

Title: Survival and clinicopathological significance of B7-H3 in bladder cancer: a systematic review and meta-analysis
Authors: Haohao sun
Fei Gao
Yuan Liu
Jianfeng Shao
Publication date: 01-12-2024
Publisher: BioMed Central
Keyword: Biomarkers
Published in: BMC Urology / Issue 1/2024
Electronic ISSN: 1471-2490
DOI: https://doi.org/10.1186/s12894-024-01446-3

2024 ASCO Annual Meeting

Springer Medicine

Survival and clinicopathological significance of B7-H3 in bladder cancer: a systematic review and meta-analysis

Abstract

Background

Methods

Results

Conclusion

PROSPERO registration

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

PROSPERO registration

Please log in to get access to this content

Other articles of this Issue 1/2024

CT findings and clinical characteristics in distinguishing renal urothelial carcinoma mimicking renal cell carcinoma from clear cell renal cell carcinoma

RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma

Comparison of Thulium Fiber Laser versus Holmium laser in ureteroscopic lithotripsy: a Meta-analysis and systematic review

Impact of a Mediterranean diet on prevention and management of urologic diseases

Increased level of serum leucine-rich-alpha-2-glycoprotein 1 in patients with clear cell renal cell carcinoma

Predictive value of SIRI and SII for metastases in RCC: a prospective clinical study